Principal Financial Group
FOLD

Principal Financial Group’s Amicus Therapeutics FOLD Stock Holding History

Principal Financial Group’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.66M Buy
529,407
+129,897
+33% +$1.86M ﹤0.01% 1456
2025
Q4 		$5.69M Buy
399,510
+136,185
+52% +$1.34M ﹤0.01% 1572
2025
Q3 		$2.08M Buy
263,325
+243,519
+1,230% +$1.73M ﹤0.01% 1807
2025
Q2 		$113K Sell
19,806
-3,613
-15% -$23.3K ﹤0.01% 2167
2025
Q1 		$191K Sell
23,419
-1,695
-7% -$15.7K ﹤0.01% 2064
2024
Q4 		$237K Sell
25,114
-2,161
-8% -$22.5K ﹤0.01% 2076
2024
Q3 		$291K Sell
27,275
-213,538
-89% -$2.33M ﹤0.01% 2031
2024
Q2 		$2.39M Buy
240,813
+2,737
+1% +$28.1K ﹤0.01% 1737
2024
Q1 		$2.8M Buy
238,076
+72,856
+44% +$932K ﹤0.01% 1723
2023
Q4 		$2.34M Buy
165,220
+27,534
+20% +$313K ﹤0.01% 1750
2023
Q3 		$1.67M Buy
137,686
+23,049
+20% +$297K ﹤0.01% 1788
2023
Q2 		$1.44M Sell
114,637
-231
-0.2% -$2.74K ﹤0.01% 1795
2023
Q1 		$1.27M Sell
114,868
-13,346
-10% -$165K ﹤0.01% 1822
2022
Q4 		$1.57M Buy
128,214
+56,034
+78% +$631K ﹤0.01% 1804
2022
Q3 		$753K Sell
72,180
-2,027
-3% -$22.6K ﹤0.01% 1882
2022
Q2 		$796K Sell
74,207
-3,875
-5% -$31.9K ﹤0.01% 1966
2022
Q1 		$739K Buy
78,082
+1,334
+2% +$12.5K ﹤0.01% 2035
2021
Q4 		$886K Sell
76,748
-31,624
-29% -$352K ﹤0.01% 2012
2021
Q3 		$1.03M Buy
108,372
+6,171
+6% +$63.1K ﹤0.01% 2001
2021
Q2 		$985K Sell
102,201
-10,859
-10% -$106K ﹤0.01% 2044
2021
Q1 		$1.12M Sell
113,060
-6,204
-5% -$96K ﹤0.01% 1968
2020
Q4 		$2.75M Buy
119,264
+26,895
+29% +$550K ﹤0.01% 1736
2020
Q3 		$1.3M Sell
92,369
-4,815
-5% -$70.2K ﹤0.01% 1819
2020
Q2 		$1.47M Buy
97,184
+25,355
+35% +$309K ﹤0.01% 1756
2020
Q1 		$663K Buy
71,829
+1,170
+2% +$11.1K ﹤0.01% 1810
2019
Q4 		$688K Buy
70,659
+638
+0.9% +$5.84K ﹤0.01% 1887
2019
Q3 		$561K Buy
70,021
+6,673
+11% +$72.4K ﹤0.01% 1923
2019
Q2 		$791K Buy
63,348
+9,121
+17% +$116K ﹤0.01% 1874
2019
Q1 		$738K Buy
54,227
+1,820
+3% +$22.2K ﹤0.01% 1871
2018
Q4 		$502K Sell
52,407
-107,094
-67% -$1.18M ﹤0.01% 1920
2018
Q3 		$1.93M Buy
159,501
+10,802
+7% +$151K ﹤0.01% 1763
2018
Q2 		$2.32M Buy
148,699
+14,051
+10% +$212K ﹤0.01% 1742
2018
Q1 		$2.02M Buy
134,648
+9,027
+7% +$137K ﹤0.01% 1735
2017
Q4 		$1.81M Buy
125,621
+103,351
+464% +$1.42M ﹤0.01% 1769
2017
Q3 		$336K Sell
22,270
-3,999
-15% -$52.9K ﹤0.01% 2003
2017
Q2 		$265K Sell
26,269
-614
-2% -$4.94K ﹤0.01% 2076
2017
Q1 		$192K Buy
26,883
+487
+2% +$3.08K ﹤0.01% 2096
2016
Q4 		$131K Buy
26,396
+3,678
+16% +$25.5K ﹤0.01% 2132
2016
Q3 		$168K Buy
22,718
+307
+1% +$2.07K ﹤0.01% 2062
2016
Q2 		$122K Buy
22,411
+2,122
+10% +$14.8K ﹤0.01% 2070
2016
Q1 		$171K Buy
20,289
+140
+0.7% +$992 ﹤0.01% 2037
2015
Q4 		$195K Buy
20,149
+540
+3% +$4.87K ﹤0.01% 2053
2015
Q3 		$274K Buy
19,609
+5,072
+35% +$79.5K ﹤0.01% 1959
2015
Q2 		$206K Buy
+14,537
New +$175K ﹤0.01% 2036

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Principal Financial Group's FOLD Position: Q1 2026 in Review

Principal Financial Group increased its Amicus Therapeutics (FOLD) stake by 33% in Q1 2026, buying an estimated $1.86M and bringing the position to 529,407 shares worth $7.66M. The position accounts for ﹤0.01% of the portfolio, ranked #1456.

Principal Financial Group first reported a position in FOLD in Q2 2015 and has held it in 44 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Principal Financial Group held 529,407 shares of Amicus Therapeutics worth $7.66M as of Q1 2026.
  • Principal Financial Group bought 129,897 Amicus Therapeutics shares in Q1 2026, an estimated $1.86M.
  • Amicus Therapeutics made up ﹤0.01% of Principal Financial Group's portfolio in Q1 2026, its #1456 holding.
  • Principal Financial Group first reported a position in Amicus Therapeutics in Q2 2015 and has held it in 44 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Principal Financial Group's 13F filing for Q1 2026, filed 4 May 2026.